1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

15 Jan 2021
Admin
News Article

Daiichi Announces Positive Results From Phase 1/2 Trial Of Ds-5141 To Treat Duchenne Muscular Dystrophy

Daiichi Sankyo Company Announced The Results Summary Of The Phase 1/2 Clinical Trial In Japan (Hereafter, The Study) Of Ds-5141 (Hereafter, The Drug) In Patients With Duchenne Muscular Dystrophy (Dmd), Which Daiichi Sankyo Is Jointly Developing With The Orphan Disease Treatment Institute Co., Ltd. (Odti).The Study Is A Clinical Trial To Examine The Safety And Efficacy Of The Drug, Which Was Administered Subcutaneously Once Weekly For 12 Weeks Followed By Once Weekly Subcutaneously Administration For 48 Weeks To Patients With Dmd.No Safety Concerns, Such As Discontinuation Or Clinically Significant Adverse Events, Were Observed In The Study. Efficacy In Terms Of The Production Of Messenger Rna With Exon 45 Skipping Of The Dystrophin Gene (The Trial&Rsquo;S Secondary Endpoint) Was Found In All Patients, And The Expression Of Dystrophin Protein (The Trial&Rsquo;S Primary Endpoint) Showed A Clear Increase In Several Patients. Analysis Of The Trial Result Is Currently Ongoing.Daiichi Sankyo Will Continue To Investigate This Study&Rsquo;S Result In Detail As Part Of Its Efforts To Provide New Treatment Options For Patients With Dmd.Ds-5141, A Nucleic Acid Drug Expected To Treat Muscular Dystrophy, Skips Exon 45 Splicing, Producing An Incomplete But Functional Dystrophin Protein During Messenger Rna Processing From The Dystrophin Gene In Patient&Rsquo;S Myocytes. In Addition, It Contains Ena Oligonucleotide, Daiichi Sankyo&Rsquo;S Proprietary Modified Nucleic Acid, As An Active Ingredient, And Received The Sakigake Designation In April 2017.Duchenne Muscular Dystrophy Is A Severe Rare Hereditary Disease With An Incidence Of About One In 3,500 Male Newborns Regardless Of Ethnicity. It Is Caused By The Deficiency Of Dystrophin Protein Production In The Patient&Rsquo;S Muscle Cells, Significantly Limiting Possible Treatments And Their Effects

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!